Thomas J. Lynch Jr., MD; Kenneth C. Anderson, MD; and Riccardo Dalla-Favera, MD, are featured.
In February, ThomasJ. Lynch Jr., MD, became director of Fred Hutchinson CancerResearch Center in Seattle, WA, replacing Gary Gilliland, MD, PhD. Most recently,Lynch was the chief scientific officer at Bristol-Myers Squibb. He has also served as director of the Yale Cancer Center in New Haven, CT, and chief of Hematology-Oncology at Massachusetts General Hospital (MGH) in Boston. Lynch specializes in novel therapies for lung cancer: While at MGH, he investigated gefitinib (Iressa; AstraZeneca) to treat EGFR-mutant small cell lung cancer.
Kenneth C. Anderson, MD, and Riccardo Dalla-Favera, MD, became editors-in-chief of Blood Cancer Discovery, a new journal of the American Association for Cancer Research (AACR). Ander-son is the director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston, MA. He has served as president of the American Society of Hematology and editor-in-chief of the AACR's Clinical Cancer Research. Anderson's research, focused on developing treatments for plasma cell disorders, has led to the approval of bortezomib (Velcade; Millennium) and lenalidomide (Revlimid; Celgene) for multiple myeloma.
Dalla-Favera is the director of the Institute for Cancer Genetics at Columbia University in New York, NY. He is also a professor of clinical medicine, as well as pathology and cell biology, at Columbia. A member of the National Academy of Sciences, Dalla-Favera is interested in the pathogenesis of B-cell malignancies such as Burkitt lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. His team studies genomic lesions that lead to the development of these diseases.
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.